top of page
About
Technology
Vaccine Pipeline
News
Contact
More
Use tab to navigate through the menu items.
All Posts
Press Releases
In the News
Search
Aug 8, 2023
Meissa's Positive Clinical Data for the First RSV Vaccine Designed to Protect Infants & Toddlers
Jun 28, 2023
Meissa Vaccines Enters into CGMP Manufacturing Agreement for Pediatric RSV Vaccine Candidate
Nov 7, 2022
Meissa's Positive Interim Clinical Data for Its Intranasal Live Attenuated RSV Vaccine for Infants
Jul 27, 2022
Meissa Vaccines Presented at The White House Summit on the Future of COVID-19 Vaccines
Jul 11, 2022
Meissa Vaccines Appoints Frank Glavin Chief Executive Officer
Dec 16, 2021
Meissa Appoints Drs. Dan H. Barouch and Mark J. Mulligan to Scientific Advisory Board
Oct 28, 2021
Meissa Announces Positive Preliminary Clinical Data on Safety and Immunogenicity of Intranasal COVID
Jul 19, 2021
Preclinical Data on Intranasal COVID-19 Vaccine Shows Protection from SARS-CoV-2 after Single Dose
Jun 30, 2021
Meissa Vaccines Begins Study of RSV Vaccine Candidate in Seronegative Children
Apr 13, 2021
Meissa Vaccines Appoints Dr. Michael Watson to Board of Directors
Mar 16, 2021
Meissa Announces IND Clearance for Phase 1 Study of COVID-19 Intranasal Live Attenuated Vaccine
Jan 21, 2021
Meissa Announces 1st Dosing in Phase 2 Study of Intranasal Live Attenuated Vaccine Candidate for RSV
Oct 14, 2020
Meissa Vaccines Expands Leadership Team as Company Advances Intranasal RSV and COVID-19 Candidates
Jun 30, 2020
Meissa Vaccines Provides a Pipeline Update on Vaccine Candidates for COVID-19 and RSV
Jan 10, 2020
Meissa Vaccines Receives U.S. FDA Fast Track Designation for Respiratory Syncytial Virus Vaccine
Sep 26, 2019
Meissa Vaccines Closes $30 Million Financing to Advance RSV Vaccine into Clinical Trials
Mar 27, 2019
Meissa Vaccines Closes $3.4 Million Financing to Advance RSV Vaccine to Clinic
Aug 3, 2017
Meissa Vaccines Announces Seed Round Investment from FundRx
Jul 12, 2017
Meissa Vaccines Awarded NIH SBIR Grant to Advance IND Preparations for RSV Vaccine Candidate
Jul 12, 2017
Meissa Vaccines Receives FDA Clearance of IND Application, Phase 1 Clinical Trial of MV-012-968
May 10, 2017
Meissa Awarded NIH SBIR Grant to Support Development of Multivalent Human Rhinovirus Vaccine Candida
bottom of page
